Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

被引：0
|
作者：
Thomas, M. [1 ]
Ponce Aix, S. [2 ]
Navarro Mendivil, A. [3 ]
Riera Knorrenschild, J. [4 ]
Schmidt, M. [5 ]
Wiegert, E. [6 ]
Kapp, K. [7 ]
Mauri, C. [8 ]
Domine Gomez, M. [9 ]
Kollmeier, J. [10 ]
Sadjadian, P. [11 ]
Froehling, K-P. [12 ]
Huber, R. M. [13 ]
Wolf, M. [14 ]
机构：
[1] Heidelberg Univ Hosp, Thorac Oncol, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H,Thoraxkli, Heidelberg, Germany
[2] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Res VHIR, Barcelona, Spain
[4] Uniklinikum Giessen & Marburg, Klin Hamatol Onkol & Immunol, Marburg, Germany
[5] Mologen AG, Early & Translat R&D, Berlin, Germany
[6] Mologen AG, Clin Dev, Berlin, Germany
[7] Mologen AG, Translat R&D, Berlin, Germany
[8] UCL, Div Med, London, England
[9] Fdn Jimenez Diaz, Dept Med Oncol, Univ Hosp, Madrid, Spain
[10] Helios Klinikum Emil von Behring GmbH, Lungenklin Heckeshorn, Berlin, Germany
[11] Johannes Weseling Klinikum, Klin Hamatol Onkol & Palliat Med, Minden, Germany
[12] Kath Klinikum Koblenz Montabaur, Klin Innere Med Pneumol, Koblenz, Germany
[13] Univ Munich, LMU Klinikum, Thorac Oncol Ctr Munich, Munich, Germany
[14] Klin Kassel, Med Klin 4, Kassel, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [1] Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
    Thomas, M.
    Ponce-Aix, S.
    Navarro, A.
    Riera-Knorrenschild, J.
    Schmidt, M.
    Wiegert, E.
    Kapp, K.
    Wittig, B.
    Mauri, C.
    Gomez, M. Domine
    Kollmeier, J.
    Sadjadian, P.
    Froehling, K. -P.
    Huber, R. M.
    Wolf, M.
    Pall, Georg
    Surmont, Veerle
    Bosquee, Leon
    Germonpre, Paul
    Brueckl, Wolfgang
    Grah, Christina
    Herzmann, Christian
    Leistner, Rumo
    Meyer, Andreas
    Mueller, Lothar
    Schmalz, Oliver
    Scholz, Christian
    Schroeder, Michael
    Serke, Monika
    Wesseler, Claas
    Brandts, Christian
    Kopp, Hans-Georg
    Blau, Wolfgang
    Griesinger, Frank
    Garcia Campelo, Maria Rosario
    Garcia Garcia, Yolanda
    Trigo Perez, Jose Manuel
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2076 - 2084
  • [2] Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S510
  • [3] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Updated results from a phase II trial.
    Shen, Bo
    Wu, Yuan
    Shi, Lin
    Pan, Banzhou
    Yang, Kaihua
    Wang, Qiong
    Zhao, Weiqing
    Han, Zhengxiang
    Wang, Lifeng
    Feng, Jifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1040 - S1040
  • [5] Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).
    Gadgeel, Shirish M.
    Ventimiglia, Jaclyn
    Kalemkerian, Gregory Peter
    Fidler, Mary J.
    Chen, Wei
    Sukari, Ammar
    Halmos, Balazs
    Boerner, Julie
    Wozniak, Antoinette J.
    Galasso, Cathy
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI).
    Shipley, Dianna
    Hainsworth, John D.
    Mekhail, Tarek
    Zubkus, John D.
    Flora, Douglas B.
    Daniel, Davey B.
    Waterhouse, David Michael
    Gravenor, Donald
    Burris, Howard A.
    Greco, Frank A.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod
    Thomas, M.
    Ponce-Aix, S.
    Navarro Mendivil, A.
    Knorrenschild, J. Riera
    Schmidt, M.
    Krikow, M.
    Wiegert, E.
    Domine Gomez, M.
    Kollmeier, J.
    Sadjadian, P.
    Froehling, K. P.
    Huber, R. M.
    Wolf, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Yao, W.
    Yu, Y.
    Zang, A.
    Cao, L.
    Lv, D.
    Li, S.
    Meng, Z.
    Zhang, J.
    Guo, Q.
    Huang, D.
    Liu, A.
    Liu, J.
    Mao, W.
    Tang, K.
    Zhang, Y.
    Chen, E.
    Wang, Z.
    Zheng, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1673 - S1673
  • [9] Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
    Gadgeel, Shirish M.
    Pennell, Nathan A.
    Fidler, Mary Jo
    Halmos, Balazs
    Bonomi, Philip
    Stevenson, James
    Schneider, Bryan
    Sukari, Ammar
    Ventimiglia, Jaclyn
    Chen, Wei
    Galasso, Cathy
    Wozniak, Antoinette
    Boerner, Julie
    Kalemkerian, Gregory P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1393 - 1399
  • [10] The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
    Browne, C.
    Ayoube, T.
    Samarasinghe, N.
    Hussaini, K.
    Warner, A.
    Black, M.
    Palma, D. A.
    Raphael, J.
    Kuruvilla, M. S.
    Blanchette, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
12345